Zevra Reports Positive Phase 2 Results for Idiopathic Hypersomnia Drug Candidate
The positive top-line results of the phase 2 trial support the safety and tolerability of KP1077.
The positive top-line results of the phase 2 trial support the safety and tolerability of KP1077.
At World Sleep 2023, Jazz Pharmaceuticals will spotlight the link between sleep disorders and cardiovascular health through 14 abstracts.
Research has revealed potential clues into the pathophysiology of idiopathic hypersomnia.
Zevra Therapeutics provided second-quarter corporate updates, showcasing progress for KP1077, a drug candidate being investigated for the treatment of idiopathic hypersomnia and narcolepsy.
Read MoreDuring the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Read MoreHarmony Biosciences reported second-quarter business updates, showcasing an upswing in prescription demand for its narcolepsy drug, Wakix.
Read MoreHarmony Biosciences selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, which provide funding toward interdisciplinary community initiatives that address challenges facing people living with sleep disorders and rare neurological diseases.
Read MoreJazz Pharmaceuticals is presenting seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy.
Read MoreThe phase 3 registrational INTUNE study will evaluate the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia.
Read MoreThe program will provide researchers with the opportunity to request and analyze high-quality data and enable individuals with primary central disorders of hypersomnolence to share their data.
Read MoreThe company also announced plans to begin a search for a new CEO to succeed Richard W. Pascoe, who will retire on June 1.
Read MoreJazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Read MoreThe phase 1 clinical trial is expected to provide additional information regarding the optimal dosing regimen.
Read MoreThe company reported business updates for the quarter ending March 31, noting continued momentum in its commercial business for Wakix, as well as in the advancement of its clinical development programs for pitolisant for the treatment of idiopathic hypersomnia.
Read MoreHarmony Biosciences announced an accelerated timeline for completing its phase 3 study evaluating pitolisant in adults idiopathic hypersomnia.
Read MoreZevra says data from its clinical program for its drug candidate to treat idiopathic hypersomnia will aid the development of treatments for rare sleep disorders through the platform.
Read MoreHarmony Biosciences spelled out next steps in its pursuit of pediatric exclusivity for WAKIX.
Read MoreThe company says the name change, a nod to the rare disease community, signifies its commitment to developing treatments for people with rare conditions, including idiopathic hypersomnia.
Read More